Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Lahousen, T; Hegenbarth, K; Ille, R; Lipp, RW; Krause, R; Little, RR; Schnedl, WJ.
Determination of glycated hemoglobin in patients with advanced liver disease.
World J Gastroenterol. 2004; 10(15):2284-2286 Doi: 10.3748/wjg.v10.i15.2284 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz
Lahousen-Luxenberger Theresa
Schnedl Wolfgang
Co-Autor*innen der Med Uni Graz
Hegenbarth Karin
Ille Rottraut
Krause Robert
Lipp Rainer
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
To evaluate the glycated hemoglobin (HbA(1c)) determination methods and to determine fructosamine in patients with chronic hepatitis, compensated cirrhosis and in patients with chronic hepatitis treated with ribavirin. HbA(1c) values were determined in 15 patients with compensated liver cirrhosis and in 20 patients with chronic hepatitis using the ion-exchange high performance liquid chromatography and the immunoassay methods. Fructosamine was determined using nitroblue tetrazolium. Forty percent of patients with liver cirrhosis had HbA(1c) results below the non-diabetic reference range by at least one HbA(1c) method, while fructosamine results were either within the reference range or elevated. Twenty percent of patients with chronic hepatitis (hepatic fibrosis) had HbA(1c) results below the non-diabetic reference range by at least one HbA(1c) method. In patients with chronic hepatitis treated with ribavirin, 50% of HbA(1c) results were below the non-diabetic reference using at least one of the HbA(1c) methods. Only evaluated in context with all liver function parameters as well as a red blood count including reticulocytes, HbA(1c) results should be used in patients with advanced liver disease. HbA(1c) and fructosamine measurements should be used with caution when evaluating long-term glucose control in patients with hepatic cirrhosis or in patients with chronic hepatitis and ribavirin treatment.
Find related publications in this database (using NLM MeSH Indexing)
Antiviral Agents - therapeutic use
Fructosamine - blood
Glycated Hemoglobin A - analysis
Hepatitis C, Chronic - blood
Hepatitis C, Chronic - drug therapy
Hepatitis, Chronic - blood
Hepatitis, Chronic - drug therapy
Humans -
Liver Cirrhosis - blood
Ribavirin - therapeutic use

© Med Uni Graz Impressum